COMP <GO>
AVNT vs CBT // RSI-14 & 200D SMA MOMENTUM
Avient Corporation (NYSE) VS. Cabot Corporation (NYSE) • 15-METRIC TALLY: AVNT 4
— CBT 7
▲ RSI-14 & 200D SMA MOMENTUM LEADER: AVNT
LAST: $42.88 (+1.64%) • MKT CAP: $3.93B
rsi-technicals
63.5
LAST: $73.85 (+0.11%) • MKT CAP: $3.81B
rsi-technicals
43.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVNT VS. CBT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AVNT | CBT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 31.20% | 25.30% | +5.90 | AVNT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.70% | 22.30% | -18.60 | CBT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.9x | 5.2x | +14.70 | CBT | /valuation <GO> |
| Free Cash Flow Yield | 4.96% | 10.25% | -5.29 | CBT | /fcf-yield <GO> |
| Operating Margin | 6.20% | 16.70% | -10.50 | CBT | /operating-margins <GO> |
| Net Profit Margin | 2.50% | 8.90% | -6.40 | CBT | /net-margins <GO> |
| Revenue Growth (YoY) | 0.60% | -7.00% | +7.60 | AVNT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.51% | 2.52% | -0.01 | CBT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 63.5 | 43.4 | +20.10 | AVNT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 44.6x | 10.7x | +33.90 | CBT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.93B | $3.81B | $120.0M | AVNT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AVNT REV | CBT REV | AVNT GROSS % | CBT GROSS % | AVNT FCF | CBT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.26B | $3.71B | 31.2% | 25.3% | $195.0M | $391.0M |
| FY 2024 | $3.24B | $3.99B | 32.6% | 24.0% | $134.9M | $451.0M |
| FY 2023 | $3.14B | $3.93B | — | — | $201.6M | $595.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVNT // BETA —
CBT // BETA —